LCTX
Lineage Cell Therapeutics, Inc. AMEX Listed Mar 5, 1992$1.26
+0.00%
vs $1.26
Mkt Cap $314.1M
52w Low $0.85
33.1% of range
52w High $2.09
50d MA $1.38
200d MA $1.60
P/E (TTM)
—
EV/EBITDA
—
P/B
6.7x
Debt/Equity
0.1x
ROE
-142.6%
P/FCF
-14.9x
RSI (14)
50.00
ATR (14)
$0.06
Beta
1.80
50d MA
$1.38
200d MA
$1.60
Avg Volume
1.2M
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
2173 Salk Avenue · Carlsbad, CA 92008 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -0.04 | 0.00 | +109.2% | 1.84 | +5.4% | +0.5% | -4.3% | +2.3% | -7.2% | -6.0% | — |
| Nov 6, 2025 | AMC | -0.02 | -0.13 | -550.0% | 1.73 | -9.2% | +1.7% | +2.8% | +0.6% | +6.0% | -6.7% | — |
| Aug 12, 2025 | AMC | -0.02 | -0.01 | +50.0% | 1.01 | -4.0% | +2.0% | -1.0% | +17.6% | +6.7% | -3.1% | — |
| May 13, 2025 | AMC | -0.02 | -0.02 | +0.0% | 0.47 | +0.0% | -2.6% | +2.7% | -1.6% | +7.4% | -2.4% | — |
| Mar 10, 2025 | AMC | -0.04 | -0.01 | +75.0% | 0.53 | +1.7% | +0.4% | -2.4% | -0.0% | +0.0% | -3.8% | — |
| Nov 14, 2024 | AMC | -0.01 | -0.02 | -53.7% | 0.89 | +5.8% | -2.3% | +1.7% | +2.7% | -29.0% | -6.5% | — |
| Aug 8, 2024 | AMC | -0.05 | -0.03 | +40.0% | 0.88 | +3.8% | +2.5% | -6.9% | -1.3% | -3.3% | +7.7% | — |
| May 9, 2024 | AMC | -0.04 | -0.04 | -4.4% | 1.18 | -2.5% | -0.8% | -6.8% | -4.6% | +4.8% | -2.8% | — |
| Mar 7, 2024 | AMC | -0.02 | -0.03 | -29.9% | 1.13 | +0.9% | +15.0% | -0.8% | -3.9% | -2.4% | -4.1% | — |
| Nov 9, 2023 | AMC | -0.04 | -0.04 | -6.7% | 1.07 | -1.9% | -2.8% | -6.9% | +4.3% | -2.5% | -3.8% | — |
| Aug 10, 2023 | AMC | -0.02 | -0.03 | -32.2% | 1.41 | +6.4% | +2.1% | -1.4% | +2.8% | -4.8% | -0.7% | — |
| May 11, 2023 | AMC | -0.02 | -0.03 | -21.9% | 1.41 | +0.7% | -2.1% | +0.7% | -2.2% | +1.5% | -2.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | Canaccord Genuity | Initiates | Buy | $9 | $1.55 | $1.56 | +0.6% | +0.6% | -6.4% | +3.4% | +1.3% | -7.2% |
| Mar 25 | B. Riley Securities | Maintains | Buy → Buy | — | $1.48 | $1.53 | +3.4% | +4.7% | -1.3% | -2.6% | -1.3% | +7.5% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.47 | $1.45 | -1.4% | +0.7% | +4.7% | -1.3% | -2.6% | -1.3% |
| Mar 6 | D. Boral Capital | Maintains | Buy → Buy | — | $1.84 | $1.94 | +5.4% | +0.5% | -4.3% | +2.3% | -7.2% | -6.0% |
| Feb 9 | D. Boral Capital | Maintains | Buy → Buy | — | $1.70 | $1.71 | +0.6% | -1.8% | +10.2% | -2.2% | -5.6% | -2.4% |
| Nov 25 | D. Boral Capital | Maintains | Buy → Buy | — | $1.75 | $1.77 | +1.1% | -0.6% | -1.7% | +2.9% | -5.7% | -3.0% |
| Nov 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.74 | $1.77 | +1.7% | +0.6% | -0.6% | -1.7% | +2.9% | -5.7% |
| Aug 27 | D. Boral Capital | Maintains | Buy → Buy | — | $1.25 | $1.28 | +2.4% | -2.4% | -0.8% | -3.3% | +4.3% | +0.8% |
| Aug 14 | D. Boral Capital | Maintains | Buy → Buy | — | $1.03 | $1.01 | -1.9% | -1.0% | +17.6% | +6.7% | -3.1% | -4.0% |
| Aug 5 | D. Boral Capital | Maintains | Buy → Buy | — | $0.97 | $0.97 | +0.3% | -1.1% | +3.2% | -3.9% | +3.5% | +2.6% |
| Jun 23 | D. Boral Capital | Maintains | Buy → Buy | — | $0.95 | $0.99 | +4.2% | +1.0% | +12.6% | -0.9% | -9.9% | -3.0% |
| Jun 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.95 | $0.99 | +4.2% | +1.0% | +12.6% | -0.9% | -9.9% | -3.0% |
| Mar 14 | B. Riley Securities | Maintains | Buy → Buy | — | $0.52 | $0.52 | +0.0% | +0.0% | -3.8% | -3.7% | +2.6% | +1.1% |
| Mar 11 | D. Boral Capital | Maintains | Buy → Buy | — | $0.53 | $0.54 | +1.7% | +0.4% | -2.4% | -0.0% | +0.0% | -3.8% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.53 | $0.54 | +1.7% | +0.4% | -2.4% | -0.0% | +0.0% | -3.8% |
| Feb 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.66 | $0.67 | +1.6% | -0.3% | -2.0% | +6.9% | +1.4% | +4.3% |
| Feb 11 | D. Boral Capital | Maintains | Buy → Buy | — | $0.66 | $0.67 | +1.6% | -0.3% | -2.0% | +6.9% | +1.4% | +4.3% |
| Jan 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.63 | $0.63 | +0.1% | -4.1% | +14.8% | -4.3% | +7.6% | -2.1% |
| Jan 10 | Maxim Group | Maintains | Buy → Buy | — | $0.53 | $0.55 | +3.1% | +9.0% | +3.2% | -8.1% | +5.3% | -1.3% |
| Jan 3 | D. Boral Capital | Maintains | Buy → Buy | — | $0.52 | $0.54 | +3.9% | +14.6% | -6.9% | +6.0% | -8.7% | +9.0% |
| Dec 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.55 | $0.55 | +0.6% | -4.5% | +9.4% | +2.6% | +2.3% | +1.4% |
| Nov 20 | D. Boral Capital | Maintains | Buy → Buy | — | $0.90 | $0.74 | -18.4% | -29.0% | -6.5% | -16.0% | +13.9% | +5.4% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.06 | $1.07 | +0.9% | +22.6% | -3.1% | -7.9% | +1.7% | -0.8% |
| Mar 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.13 | $1.14 | +0.9% | +15.0% | -0.8% | -3.9% | -2.4% | -4.1% |
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.08 | $1.10 | +1.9% | -5.6% | +1.0% | +9.7% | +0.0% | -3.5% |
| Feb 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $0.98 | $1.02 | +4.1% | +6.1% | +6.7% | -5.4% | +2.9% | +0.0% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.41 | $1.50 | +6.4% | +2.1% | -1.4% | +2.8% | -4.8% | -0.7% |
| Jul 25 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.40 | $1.39 | -0.7% | -2.9% | +2.9% | -0.7% | +1.4% | +8.5% |
| Jul 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.42 | $1.42 | +0.0% | -1.4% | -2.9% | +2.9% | -0.7% | +1.4% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.41 | $1.42 | +0.7% | -2.1% | +0.7% | -2.2% | +1.5% | -2.9% |
No insider trades available.
8-K · 2.02
!! High
Lineage Cell Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Lineage Cell Therapeutics released Q1 2026 financial results, with detailed earnings data available in their press release exhibit for investor review.
May 12
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
LCTX established an at-the-market offering program, allowing the company to raise capital opportunistically at current market prices, which could dilute existing shareholders but provides flexible funding without immediate dilution.
Mar 11
8-K
Lineage Cell Therapeutics, Inc. -- 8-K Filing
Lineage Cell Therapeutics reported fourth quarter and 2025 full-year financial results and will discuss operational progress during today's earnings conference call.
Mar 5
8-K · 5.02
!!! Very High
Staar Surgical Co -- 8-K 5.02: Executive Change
Staar Surgical appoints Warren Foust as CEO effective February 1, 2026, promoting the CFO to Vice President, signaling leadership transition that may affect operational strategy and investor confidence.
Feb 2
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 2
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Ultra-Small Company Market Fund | 221,000 | $349K | Mar 2026 |
| 2 | Guggenheim Active Allocation Fund | 747 | $1K | Feb 2026 |
Valuation
Market Cap
$314.1M
Enterprise Value
$234.2M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.03x
P/B
6.69x
P/S
19.62x
P/FCF
-14.91x
EV/EBITDA
—
Shares Out
230.1M
Financials (TTM)
Revenue
$14.8M
Net Income
-$64.2M
EBITDA
-$43.1M
Free Cash Flow
-$19.4M
Op Cash Flow
-$18.9M
EPS Basic
$-0.28
EPS Diluted
$-0.28
EPS Forward
$-0.04
Gross Margin
98.0%
Op Margin
-255.1%
Net Margin
-434.4%
Balance Sheet
Total Assets
$112.6M
Total Liab.
$69.2M
Total Equity
$43.3M
Cash
$55.8M
LT Debt
$0
Book Value/Sh
$0.19
Debt/Equity
0.05x
Current Ratio
5.20
Quick Ratio
5.20
Returns & Growth
ROE
-142.6%
ROA
-56.4%
ROIC
-19.8%
Rev Growth YoY
+53.2%
EPS Growth YoY
-201.1%
Price Returns
2W
+1.5%
1M
-11.9%
3M
-30.7%
6M
-24.4%
12M
+100.1%
Technicals
52W High
$2.09
52W Low
$0.85
50d MA
$1.38
200d MA
$1.60
RSI (14)
50.00
ATR (14)
$0.06
Beta
1.80
Avg Volume
1.2M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 6:42pm
· Source: financialmodelingprep.com